Archive: 24/03/2019
Patients bear increased financial burden for growth hormone treatment despite FDA approval
Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time, according to findings from researchers at ...
Mar 24, 2019
Obesity speeds up the start of puberty in boys, study finds
Girls are not the only ones who go through puberty early if they have obesity. Boys with obesity enter puberty at an earlier age than average, according to a study that will be presented Sunday at ENDO 2019, the Endocrine ...
Mar 24, 2019
Autoimmune diseases are related to each other, some more than others
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others. These ...
Mar 24, 2019
Investigational obesity drug, oxytocin, weakens brain's reward signals for food
The hormone oxytocin reduces the communication between different brain areas involved in the cognitive, sensory and emotional processing of food cues that people with obesity demonstrate when they look at high-calorie foods, ...
Mar 24, 2019
Cost savings from growth hormone insurance strategies not passed on to patients
Increasingly aggressive insurance strategies have lowered the total costs and insurance costs of growth hormone drugs, but those savings are not being passed on to patients, according to new research to be presented Sunday ...
Mar 24, 2019
Genetic rickets improves more with burosumab than standard care, study finds
Burosumab, a new injectable medicine to treat X-linked hypophosphatemia (XLH), an inherited form of rickets, demonstrates superior improvements in rickets and other outcomes compared with conventional therapy in an international, ...
Mar 24, 2019